By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

Canadian Breast Cancer Network

Donate Now

What breast cancer drugs are available in Canada

MedSearch

Generic Name

Trastuzumab deruxtecan

Brand Name

Enhertu
HER2-low
Stage IV (metastatic)
Targeted Therapy
AstraZeneca Canada Inc.
Injectable
British Columbia, Quebec
Alberta, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Quebec, Saskatchewan, Yukon
No
Listed on Provincial Drug Formulary

For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

For the treatment of unresectable or metastatic locally advanced breast cancer slightly overexpressing the human epidermal growth factor receptor type 2 (HER2).

Approved for reimbursement in Quebec (with condition of reduced price, and supervised use).

Yes

The AstraZeneca Oncology Patient Support Program will be expanded to patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Patients with HR+ breast cancer should have received at least one and be no longer considered eligible for endocrine therapy. For eligible HR+/HER2-low metastatic breast cancer patients, the PSP will offer reimbursement navigation support; co-payment towards the cost of the drug (up to 20 percent) for those with private insurance and who are paying out of pocket; and a free drug program which offers financial support for Enhertu at full coverage for eligible patients who do not have private insurance and who have enrolled in the PSP between January 9, 2023 and January 31, 2024, or until public listing (whichever comes first). It is important to note: HR-/HER2-low patients will be eligible for reimbursement navigation support, educational resources and co-payment towards the cost of the drug (up to 20 percent) for those with private insurance or who are paying out of pocket, but will NOT be eligible for free drug at this time.

Health Canada Drug Monograph
New Search

Disclaimer

FAQ's

  • Generic vs. Brand Name

    What is the difference between a Generic drug and a Brand Name drug?

    Brand name, or innovator drugs are drugs that are researched, developed and marketed by a specific pharmaceutical company. After a pharmaceutical company researches and gains approval to develop a drug they apply for a patent, allowing them to exclusively produce and sell that drug.  Patents on drugs often have an expiration date. Once the patent runs out other pharmaceutical companies are free to produce and sell the drug as well. A generic drug is a copy of the original brand name drug and uses the same active ingredients but is simply being developed by another pharmaceutical company. Generic drug manufactures are required to follow the same manufacturing and safety standards as brand name manufactures.

    For more information about the difference between generic and brand name drugs, visit the Canadian Agency for Drugs and Technologies in Health (CADTH). 

  • Provincial/Territorial Formularies

    What is the contact information for my provincial/territorial formulary?

    A list of formularies and their contact information is available HERE.

  • Income Support Programs

    Where do I find more information on income support programs to fund the cost of my drugs in my province/territory?

    Use our FinancialNavigator Database to find provincial and federal governmental income support programs and other avenues of financial support by searching “Income Supplement” and your province.

  • Manufacturer Patient Assistance Programs

    How do I contact the manufacturer to inquire about whether or not a portion of, or all of the costs of a drug is covered through their Patient Assistance Program?

    You can search for all available manufacturer Patient Assistances Programs and more avenues of support on our FinancialNavigator by searching “Drug Coverage”. You can also visit Drug Access Canada for more resources on accessing breast cancer drugs in Canada.

  • Drugs that aren’t covered on a formulary

    How do I access drugs that aren’t covered on a provincial/territorial formulary?

    Learn more about programs that may help cover drugs that aren’t listed on the public formularies HERE or by searching our FinancialNavigator Database.  

    What is the Trillium Drug Program in Ontario, am I eligible and how do I apply?

    Read this Q & A fact sheet for more information on this program and how it can potentially help offset the costs of your take home cancer medications.

  • Private Insurance

    How can my private insurance help pay for drugs that aren’t covered through public funding?

    Find more information about private insurance HERE.

  • Drug approval process in Canada

    Where do I find more information about the drug approval process in Canada?

    Learn more about the drug approval process in Canada HERE.

  • Clinical Trials

    Where do I find more information about clinical trials in Canada?

    Learn more about metastatic breast cancer clinical trials in Canada HERE. 

  • Cancer Centres in Canada

    Where do I find a list of cancer centres and contact information?

    A list of cancer centres in Canada and their contact information is HERE.

  • Additional Information

    I have information to help update this tool, who do I contact?

    If you have additional information that would be helpful to include in this tool please email cbcn@cbcn.ca or call us at 1-800-685-8820.

  • Contacting CBCN

    How can I connect with CBCN directly about specific questions?

    Connect with us via email at cbcn@cbcn.ca or on the phone at 1-800-685-8820.

  Receive updates by email Subscribe Now

About CBCN

CBCN strives to voice the views and concerns of breast cancer patients through education, advocacy activities, and the promotion of information sharing.

Canadian Breast Cancer Network
185 Somerset St. West Suite 318, Ottawa, ON Canada  K2P 0J2
 Tel: 613-230-3044
Toll-free: 1-800-685-8820
Email Us

Information
Education
Action
Contact
MEDSEARCH
Where breast cancer drugs are available in Canada

Quick Find

Connect with Us

® CBCN  |  Charitable Registration No. 889802971 RR0001

Web Design McGill Buckley  |  Powered by Quicksilk

Disclaimer  |  Privacy Policy  |  Contact Us